만성 판상 건선 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global chronic plaque psoriasis market size is expected to reach USD 2.61 Billion in 2034 from USD 1.36 Billion in 2025, growing at a CAGR of 7.56 during 2026-2034.This market is experiencing strong growth due to the increasing prevalence of chronic inflammatory skin disorders and growing awareness regarding treatment options. Chronic plaque psoriasis is one of the most common forms of psoriasis and often requires long-term disease management. Improvements in diagnosis, patient education, and access to advanced therapies are contributing significantly to market development.

Major growth drivers include advancements in biologic therapies, increasing healthcare expenditures, and rising demand for personalized treatment approaches. Pharmaceutical companies are investing heavily in innovative drugs that target specific immune pathways to improve treatment outcomes. Additionally, growing awareness among patients and healthcare professionals is encouraging earlier diagnosis and intervention.

The future outlook remains highly favorable as research into novel immunological treatments continues advancing. Development of next-generation biologics, oral therapies, and personalized medicine approaches is expected to create new growth opportunities. Expanding healthcare access and improved reimbursement frameworks will further support treatment adoption. As demand for effective long-term disease management solutions increases, the market is expected to witness sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Class

• Biologics
• Small Molecule Drugs

By Route Of Administration

• Injectable
• Oral
• Topical

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

COMPANIES PROFILED

• Pfizer Inc, Johnson & Johnson, Merck & Co. Inc., AbbVie Inc, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc, Boehringer Ingelheim International GmbH, Biogen Inc, UCB S.A., Dr. Reddy's Laboratories Ltd, Innovent Biologics Inc, Dong-A ST Co. Ltd, Alumis GmbH Co. KG

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHRONIC PLAQUE PSORIASIS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Biologics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Small Molecule Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CHRONIC PLAQUE PSORIASIS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CHRONIC PLAQUE PSORIASIS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CHRONIC PLAQUE PSORIASIS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CHRONIC PLAQUE PSORIASIS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Johnson & Johnson
  • 9.2.3 Merck & Co. Inc
  • 9.2.4 AbbVie Inc
  • 9.2.5 Bristol-Myers Squibb Company
  • 9.2.6 Novartis AG
  • 9.2.7 Eli Lilly And Company
  • 9.2.8 Amgen Inc
  • 9.2.9 Boehringer Ingelheim International GmbH
  • 9.2.10 Biogen Inc
  • 9.2.11 UCB S.A
  • 9.2.12 Dr. Reddy's Laboratories Ltd
  • 9.2.13 Innovent Biologics Inc
  • 9.2.14 Dong-A ST Co. Ltd
  • 9.2.15 Alumis GmbH Co. KG